Founder and Managing Director
Gregg applies more than 20 years of experience in the life science and technology industries, ranging from venture-backed start-ups to publicly traded companies. He previously served as CFO of two public and three privately held companies, during which time he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a BA from Middlebury College, JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.
Founder and Managing Director
Daniel brings more than 30 years of experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, he has participated in seven initial public offerings. Over the course of his career, he has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
Steve has more than 30 years of experience in life sciences and healthcare, including founding two start-ups and working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. He previously served as CFO of two public companies and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients. He has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development, and manufacturing functions. Steve participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, led the effort to take RXi public, and has extensive experience in international fundraising and corporate structuring. He was formerly Chairman of Cognoptix and is on the Board of Phytera, Inc. Steve’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. He holds a BS from the University of Massachusetts and MBA from Babson College.
As President, Chris oversees Danforth’s internal operations team as well as the growth and expansion of the company and its service offerings. Prior to joining Danforth, Chris spent nearly 15 years in senior leadership positions at Vistaprint, where he was instrumental to the company’s growth from start-up operations to achieving over $1 billion in revenue. Among his responsibilities, he led the strategic direction and roll-out of new customer support services, as well as the infrastructure design and personnel needs required for their operation. He most recently served as the company’s Senior Vice President of Technology and Transformation, overseeing all aspects of software development and people operations. Prior to joining Vistaprint, Chris spent seven years as a senior technical consultant at Envisa and Accenture. He holds a BS in Management Information Systems from Babson College.
Chief People Officer
Valeria joined Danforth in 2020 as the company’s first Chief People Officer, applying expertise in both consulting and talent management to oversee strategy and processes around culture, recruitment and retainment. She previously spent ten years at The Boston Consulting Group, where she most recently served as Consulting Team Talent Manager. In this role, she led talent strategy for approximately 100 employees, including responsibility for staffing, affiliation, performance evaluations, career development, mobility, diversity and inclusion, mentorship and mental health initiatives. She was awarded the firm’s global Key to Purpose award for embodying “growth by growing others.” Valeria previously led strategic growth efforts for companies including Iron Mountain, Univision Networks and Skype. She holds a BA from Harvard University and MBA from London Business School.
Managing Director, Clinical Business Operations
Tony is an outsourcing expert with nearly 40 years of progressive and diversified experience in negotiation and management of research and development contracts. His leadership roles have included the development of outsourcing process/procedures, developing corporate strategies, selecting strategic partners, and governance and alliance management. He has additionally led tactical sourcing activities such as development of RFPs, evaluation and selection of best-in-class providers, negotiation of new and amended MSAs and SOWs, management of vendor performance and issue resolution. Prior to his role with Danforth, Tony founded CTB Solutions, Inc. to provide strategic and tactical clinical outsourcing services to clients ranging from the emerging biopharma space to mid-to-large pharmaceutical companies. His prior experience as the Director of Global Clinical Outsourcing at Otsuka and in senior business development and contracts management roles at Parexel makes him uniquely qualified to understand both the sponsor and provider positions. He holds a BA from American University.
Managing Director, Mid-Atlantic
Barb’s experience spans life science start-ups to commercial-stage companies, including expertise in financing strategy and execution, IPO readiness, SEC reporting, cash flow and treasury, budgeting and accounting for complex debt and equity transactions. She most recently served as CFO of Enterin, Inc. where she established the financial infrastructure to support the company’s progress in its clinical trials. She previously held finance leadership roles at Egalet Corporation (now Zyla Life Sciences), Sobi, Inc., Topaz Pharmaceuticals, Inc. (acquired by Sanofi-Pasteur), Genaera Corporation and Vicuron Pharmaceuticals, Inc. (acquired by Pfizer). Barb is additionally experienced in consulting, having served as Director of Client Service at Resources Global Professionals (RGP). She began her career as an auditor at Deloitte. She is a CPA and holds a BS in Accounting and MBA in Pharmaceutical and Healthcare Marketing from St. Joseph’s University.
Managing Director, New York Metro Region
Heather joined Danforth in 2015 with nearly 30 years of experience spanning private and public, start-up and later-stage organizations in the medical equipment and pharmaceutical industries. As an operational CFO, she has implemented strategic plans into corporate operations across functional areas including human resources, finance and accounting, research and development, manufacturing, quality, sales and marketing departments, while maintaining exceptional financial control and transparency to all stakeholders. Her Danforth clients have included Homology Medicines, Immuneering, Kallyope, Opsonix, Pear Therapeutics and SpringWorks Therapeutics, among others. Prior to joining Danforth, she held finance leadership roles for Cytonome and AutoImmune. Heather earned a BA from the University of California, San Diego, and MBA from the University of Michigan Graduate School of Business.
Managing Director, New England
Jon joined Danforth in 2018 with 25 years of experience in financial and executive management at emerging and growth-stage life science companies and in investment banking. As a former CFO, he raised more than $300 million of equity and debt in public and private securities offerings, including a $110 million IPO at Altus Pharmaceuticals, and led strategic and business development transactions including the successful sale of Xcellerex to GE Healthcare. He most recently served as CFO of Histogenics Corporation, a publicly-held cell therapy company developing products for the orthopedics market. He additionally held the roles of CFO for Metamark Genetics, Inc. and CFO and Treasurer of Repligen Corporation. Previously, Jon was an investment banker for 10 years, during which time he originated and executed on numerous corporate financings and merger and acquisition transactions at SG Cowen and Salomon Brothers Inc. He received a BS in Business Administration and Finance from Boston University and an MBA in Finance from New York University Stern School of Business.
Managing Director, West Region
Jeff joined Danforth in 2017 to lead the firm’s growth in the western US, based in Colorado. He brings more than 25 years of experience to the role, both as a former investment banker and a strategic financial executive with expertise in operations and transactions for private and public companies. He previously held senior leadership positions for Great Basin Scientific, GlobeImmune, AlgoRx Pharmaceuticals and Antigenics, and later formed a successful life sciences financial advisory practice. He has raised more than $500 million for start-up companies and also led multiple liquidity events. Jeff began his career at Coopers & Lybrand and UBS Investment Bank, and holds a BS in Accounting from Case Western Reserve University.
Managing Director and Practice Lead, Digital Health
Bill joined Danforth in 2016 to build and lead the Healthcare Technology/Digital Health platform. As a passionate and seasoned CFO with over 25 years of strategic financial and operational management experience, Bill has successfully navigated several companies through rapid growth. His broad experience includes executive leadership with high growth and commercially driven healthcare technology and life science companies such as Humedica (sold to UnitedHealth), NaviNet (sold to Lumeris), SynapDx and ZappRx. Bill has led several successful M&A initiatives, including the highly strategic sale of Humedica to UnitedHealth in 2013. He is recognized for scaling, managing and leading rapidly growing health technology companies and has a successful history of financing via public/private equity transactions, raising more than $300 million. Bill holds a BA from Villanova University and MBA from the University of Massachusetts.
Managing Director, New England
Lance has more than 30 years of experience as a life science CFO and senior executive. He brings extensive knowledge in IPO preparations and post-public SEC compliance, as well as financial operations and strategy at all phases of the corporate life cycle, including capital financing, corporate governance and investor and banking relations. He has served over 20 life science companies as interim CFO or C-level advisor, including Pieris Pharmaceuticals, Proteostasis Therapeutics, Stoke Therapeutics, Centrexion Therapeutics and NextCure. Prior to joining Danforth, Lance spent 12 years at PricewaterhouseCoopers, where he was an integral member of the Transaction Advisory Services Global Capital Markets Group in London, England. He is a CPA and holds a BS in Accountancy from Bentley College.